Efficacy and safety of fluorouracil + epirubicin + cyclophosphamide (FEC) versus FEC + docetaxel in patients with high-risk node-negative breast cancer.

Trial Profile

Efficacy and safety of fluorouracil + epirubicin + cyclophosphamide (FEC) versus FEC + docetaxel in patients with high-risk node-negative breast cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2012

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms NNBC3-Europe
  • Most Recent Events

    • 08 Dec 2012 Results presented at the 35th Annual San Antonio Breast Cancer Symposium.
    • 08 Dec 2012 The primary endpoint 'Disease-free-survival-rate' has not been met, as reported in SABCS abstract.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top